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Tbe inftuence of prostaglandins on renal function changes induced by fumsemide was analyzed in 21 non-azotemic cirrhot- 
ic patients with ascites. Patients were studied in two periods of 120 min immediately before and after furosemide infusion 
(20 mg, ev). Furosemide czuscd x increase in creatinine clearance in 15 patients (group A: 99 + 7 vs. 129 f 5 ml/min; 
mean f SE) and a reduction in the remaining six (group B: 102 + 13 vs. 71 ?: 9 ml/min). Parallel changes were observed 
in the urinary excretion of 6.Keto-prostaglandin-F,. (metabolite of renal prostacyclin) which augmented after forosemide 
in 14 of the 15 patients from group A(478 f 107~s. 1034 f lRpglmin.p < 0.001) and decreased in all patients from group 
B (1032 + 240 vs. 548 + 136 pg/min, p < 0.0s~. In contrast, the urinary excretion of prostaglandin El was stimulated by fur- 
osemide in all patients (group A, 92 f 19 vs. 448 f 60 pg/min, p < 0.001; and group B, 7.W f 63 vs. 361 f 25 pglmin, p 4 
0.05). In all of the patients furosemide-induced changes (post- minus pre-fumsemide values) in creatinine clearance were 
closely correlated in a direct and linear fashion with those in 6.Keto-prmtaglattdir-F,, (I = 0.74; p < O.CQl). These 
changes were associated with a higher furosemide-induced natriuresis in group A than in group B (641 f 68 vs. 302 + 46 
pmoUmin. p < O.Wl). In the basal period urinary 6.Keto-prostaglsndin-F,. was significantly higher @ < 0.05) in group B 
than in group A, no differences being found in the remamiog parameters, including plasma renin activity (group A, 9.7 f 
2.6 vs. group B, 12.0 f 3.9 @ml per h) and urinary sodium output (group A, 30.1 f 10.6 vs. group B, 11.8 + 3.5pmoV 
mm). In summary, our results suggest that renal prostacyclin metabolism influences renal response to fumsemide in dr- 
rhotic patients. 
The mechanisms underlying the dcvelapment of amte- 
mia in some cirrhotic pattents with asdtcs undergoingsus- 
tained furosemide therapy have not been fully defined (t- 
6). Although furosemide inducts volume depletion and 
angiotensin II generation that can justify azotemia in 
some cases (5.6), profound impairments in renal function 
and renal plasma floe have been demonstrated immedi- 
ately after a single dose of furosemide in patients in which 
these two alterations wire absent (17). These complica- 
tions cannot be predicted from clinical or analytical data 
and they seem to be unrelated to the degree of hyperreni- 
nism or to the status of renal function before diuretic chat- 
lenge (7). Furthermore, recen! data indicate that prosta- 
glandio- (PG) E, and thromboxane A, exert little or no in- 
fluence on changes in renal function and renal hemody- 
namics observed in cirrhotics with nscitcs immediately af- 
ter furosemide administration (7.8). However, furose- 
mide-induced renal vasodilation is absolutely abolished 
by inhibitors of PG synthesis (9.10). 
Prostacyclin is a powerful renal vasodilatory PG, which 
plays a crucial role in protecting renal function against 
vasopresroragentsinas~iticpaticnts(ll). Thissubstance. 
whose renal synthesis is increased by furo~mdc in pa- 
rims with hvcr cirrhom (8). has been found to be m- 
valved in the changes of glomrrular fun&m inkcsd by 
this diureuc m healthy ammals (12). In this study WC ana- 
lyzed whether renal prostncyclin influences the rwponx 
of renat function to a single dose of i.v. furnsemidc in non- 
azotemic cirrhoticr with ascites. 
Patients nrrd Mcthtis 
T,wnty-one p::ixa (!S men. tbrcc wamcn: wirh cir 
rhosir, ascites and preserved renal function were studied. 
The diagnosis of cirrhosis was established by liver biopsy 
andim laparoscopy, and the presence of arcites was 
proved by diagnostic paraccnterir in all cases. Patients 
wiih gastromtestmat bleeding. hepatic encephalopathy, 
infection, past 01 present history of csrdiovaswlar dis- 
ease, diabetes mellitus, neoplasia. functional renal failure 
or diiical or analytical data of parenchymal renal disease 
were not included in the study. 
In the 4 days before the study, patienti were give11 a 
diet mntaimng MI mm&day of wdium and were main- 
tained on bed rest, and therapy Yrith diuretics, PG synthe- 
sis inhibitors, vanactive sub,tancea or any other drag 
able to modify renal hemodynamin OT fun&x was w:h- 
drawn. Indeed, no patien? taking qironolactcme, gluco- 
conicbids or non-sleroickd an:iinflammnory drugs m the 
preceding 7 days was included in the study. 
After an overnight fast and bed rest. patients were stud- 
ied in the morning of the fifth day. After bladder ewcua- 
tion, 5 cc of water/kg c,f body weight were given orally at 8 
;c.m. tomaintain unne ilow. All urinewas collected in two 
consecutive periods of 2 h immcdiat&;y before (g-10 
a.m.) and after (15-12 a.m.) the imravenous administra- 
tion of 20 mg of funxemide (Seguril, Hoechst Iberia 
Labs., Spain). Blued samples obtained at 9 and 1 I d.m.. 
and urine ahquols of each period wzre used ior analytical 
determinations. In all paiients urinary voPlme (UV), uri- 
nary sodurn excretion {UN&), crcarininc clcarancc 
(CCr), fractional sodium excretion (FENa), and the uri- 
nary excretion of PGEz (UPGEL) and of 6-Keto-prosta- 
glandin&, (U-6.l&to-PGF,,), the stable urinary aetab- 
elite of renal prostacyclin, were detetined in both peri- 
ods of the study, while plasma renin activity (PRA) was 
measured only in the basal one. 
Ek?clrotyles and creatinine were measured in rerum 
and urine by flame photometry and Jaffe’s chromogen 
rcactmn. respectively. Liver functwn parameters were 
derermmed by standard me:hods. Blood ior PRA was col- 
Ircicd in EIJTA. immediarely procerser, at 4 “C and rhc 
rerv stored at -40 “C. PRA was estimated by radioimmu- 
noaasvy For anginxensin 1 (Cea Sorin. France). Urine SPIII- 
pies for PG quantitstion, were collected on ice in lysine- 
axtylsaticylate awl frozen at -40 “C umil use To derer- 
mine UPC& and Ud-Keto-PGF,,_ p&r lipids were ex- 
iracted firm urine aliquots (IO m!! on disposable C-18 
cartridges (Ssp-Pak. Waters ASSOC.. Milford, MA. 
U.S.A.) (13t. being hnth m.etabolitesmen~uredin the re- 
~~1ltm1 eluate~ hy -pccific radioimmuno;~ssays m pre- 
wausty described (14). Mew recoveries lnnr PGE, (82 t 
4%) and for h-Kcto-PGF,, (79 ? 3%) were calculated by 
the addition of labelled PGE, and h-Keio-PGF,, IO five 
unne aliquors b&r: prwcssing. Theur: mean valueswere 
used for corrections in all ssmpleu. In Ii norm31 subjects 
under a rimilur protocol. mean values of U-&l&m-PGF,, 
and II PGE, were 191.8 + 28.4 and 272 f 83.1 pg/min, 
reepecriveiy The administration of indomerhacin (ItM mg 
twice the day before urine wllcclion) to these controls 
significantly inhibited the urinary excr&m of both me- 
taholiter (Xi.7 f 5.2%. p < Ml; and h3 I 6.4s.~ < 
0.01, rcspcctively). Tritinted BKero-PGF,, nnd POE, 
(Ill0 DtM dpm) were used as srsndards. Annserum against 
6.K&o-PGF,, WBS raised from rabbits in 0-1 laboratory 
bb the method oTKirton et al. (15). with its blnding char- 
acteristics and cross-reactivities as reported elsewhere 
(14). Antiserum for PGE,was obtained from the Pasteur 
Invirurc (France). and its cross-reactivities with olher 
prwtanoida were as follows: 0.11% with PGF2.; 0.01% 
wrh PGF,,, and less than 0.01% with TX&, PGDi and h- 
Kayo-PGF,.. All samples in a single balcb were derer- 
mined m duphcate to minimize errors due to interassay 
variation 
Errultr are expressed 8s mean 2 SE. Cornpa-vr=tw 
twccn gruupr were made by vxian~c dnalysia. Tbc Stu- 
dent I-test for paired data or the non-parametric W+tcoxon 
tat were used for intragroup cumparisuns IS indicr!rd. 
Regression analysis was performed by the least-squares 
method. 
Patrenrs were retrospectively divided into two groups 
according 10 the furoscmide-induced change in CCr (port- 
minus pre-furosemide values). In 15 patients (group A), 
CCr increased in response m furosemide (mean change: 
30.3 ? 5.6 mlimin; +30.6%). whereas in the remaining 
six (group B) changes of CCr were negative (mean 
chnngc: -31.4 C 6.3: mlimin:-30.8%). 
Mc;*n age (A. 59.3 f 3.3; B. 52.3 zk 3.R years: N.S.). 
mslelfemale ratio (A, 13/2; 8. 511). etiology of cirrhosis 
(A, 12 alcoholic, three past-necrotic; 8. five alcoholic, 
one post-necrotic). mean arterial pressure (A, 81.4 f 3.4; 
8.79.1 2 3.6mm He: N.S.I. as wellas basicanalvticalw- 
rameters and PRA kels (Table 1) were sin& in bbth 
groups. 
Table 2 summarizes mean values of renal function pa- 
rameters before and after furosemide in both groups. 
Before furosemide no significant differences were 
found between groups in CCr, UNaV. UV nor FENa, al- 
though UNaV and FENa tended to be lower in group B 
than in group A. In the post-furoscmide period, mean 
values of these parameters were significantly higher in 
group A than in group B. with the reception of FENa 
which was similar in both groups. 
Lrrinary excrcrion of rer,al PG metabolites 
Individual values of U-6.Keto-PGF,. and UPGE, in 
the two periods of the study are represented in Figs. 1 and 
2, respectively. 
In the basal period, U-6.Keto-PGF,. was significantly 
lower in group A than in group B, whereas no significant 
differences were found in UPGE, levels. althaueh it 
tended to be higher in group B. In response to furose- 
mide, UPGE, increased in all patients, with post-furcse- 
mide levels significantly higher than those in the basal pe- 
riod in both groups. However, U-6.Kets.PGF,. was m- 
creased after furasemtde in 14 patients, all of them from 
group A. In the :emaining seven patients (one from glaup 
A and all from group B) this metahclite decreased after 
furosemide. As a result. as compared with baaedne levels, 
mean values of WSKeto-PGF,. were rigniiicantly in- 
creased and deereaced in groups A and 8, respectively. in 
response to futoremide. 
The absolute furosemide-induced response (obtained 
by subtracting pre- from past-furosemide values in each 
TABLE 3 
groups A and B. 
patient) in the urinary excretion of PG as well as in renal 
function parameters ib showed in Table 3. 
Finally, when dll patients were taken together, furose- 
mide-induced changes in CCr were closely correlated 
with tLne m U-&Keta-PGF, (I = 0.75:~ c. O.MI) (Fig. 
3) and. to a iesser extent, with those in U-PGE2 (r = 0.51; 
:I < 0.35) In addition, the changes in each metabolite COT- 
related among them in a iinesr and direct fashion (r = 
0.55: p < 0 05) However, a multiple correlation obtamed 
by plotting furoeemide-induced changes in CCr agamst 
those in U-6.Keto-PGF,, and UPGE_. disclosed that only 
the levels of the former metabolits influenced stgmficant- 
ly changes in CCr. 
Dfscussion 
?hrr study was designed to evaluate whether the acute 
effects of furosemide on renal function in non-azoteniirc 
cirrhotics with ascites are mfluenced by renal prortacy- 
clin. Renal prustacyclin synthesis was assessed rbrough 
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the ,,,ci,surcmc,,, of U-6.Kern--PGF,,. Although a frac- 
tion of this urinary ntetaholite probably arises from prew 
nnl sources. its quontitation is a widely accepted method 
for menwring the production of prostacyclin by the kid- 
ncpn. smce .reverrd studies (16-18). including recent data 
from cirrhotic patients (19). support a markedly prcdomi- 
nant renal origm for the U-6-Kcto-PGF,, present in 
urine. 
Present results confirm earlier observations and dem- 
onstrate 4.1 acute impairment of renal function in some 
cirrhotic patients with ascites following furosemide ad- 
ministration (7). Other studies have pointed out that the 
renovascular effects of furoaemidc are partially depen- 
dent on the stimulation of the renal synthesis of vasodila- 
tory prostaglandins induced by this diuretic (9). Recently, 
no differences were observed in pre- or post-furosemide 
levels of UPGE* between cirrhotic patients showing in- 
creases or deczeases of renal plasma Row after the diuret- 
ic. Thus. a primaly role for PGE, in the hemodynamic ef- 
fects of furosemide seems to be unlikely. lo contrast. the 
parallel changes CL CCr and U-6.Keto-PGF,, observed 
after furosemidc administration in this study. suggest that 
renal prostacyclin may modulate, at least in part, the 
acute glomrrular effects of this diuretic in cirrhotic pa- 
tients. 
Associated decreases of renal plasma flow and glome- 
NIX filtration rate have been demonstrated in some cir- 
rhotics wth ascites tmmediately after furosemide admin- 
istration (7). It is conceivable tint the fall of CCr observed 
in patients from group B in this study is secondary to a de- 
crease in renal blood flow. In cirrhotic patients with as- 
cnes renal blood flow nod CCr depend on an equilibrium 
between vasoconstrictor and vasodilatory forces acting on 
rhe kidney (11). Yawconstrictor agents were not mea- 
surea after %:;,emidr 5 our :.tudy. However. it may he 
Y?-:!abiy arsumd that group B patients were exposed 
to increased wsoconstnctor influences since they ex- 
hibited mean basal levels of plasma renin activity exceed- 
ing the upper normal limit by about 5 times, and furose- 
mide has been sh:,wn to increase the release of pressor 
agents shortly after its administration (12). In such a situa- 
tmn. ii drop m renal vasodilators should he expected to 
determme an impa irmrnt of both renal blood flow and re- 
nal function. as u as found in patients from group B in 
which both CCr and IJ-6-Keto-PGF,, were reduced in the 
post-furosemide pleriod. On the other hand, in patients 
::om group A, whose plasma renin activity levels were 
also supranormal before diunctic challenge. CCr was 
raised after furosemide. in association with a marked in- 
crease in U-6-Keta-PGFI,. Overall. these data are in 
agreement with tx idea that renal vasodilatory prosta- 
glandlns contribute to maintain renal function in cirrhotic 
patients by counwracting the effeas of pressor hormones 
01). 
Non-steroidal antiinflammatory drugs. whose primary 
action is the inhibition of prostaglandin synthesis, have 
been shown to impair renal function in cirrhaic patients 
with ascites and increased vawconstrictor tone 
(11,20,2L). Thus. our results suggest that the dctcricra- 
tion of CCr in patients from goup B may reflect a shift in 
renal VBSO~D~O~ equilibrium toward vasocanstricthn. 
secondarily to the drop in reaal prostacyclin synthesis. 
Although unlikely. the possibility that changes in CCr 
might induce parallel modifications of renal provtscyclin 
synthesis or the urinary washout of U-6.Keto-PGF,,, can- 
not be exciuoed. Thus, this alternate explanation should 
he kept in mind to interpret findings in this study. 
Increases of both LJPGE, (all patients) and U-6.Keto- 
PGF,, (group A) arc consistent with the well-known stim- 
ulatory effect of furosemide on the cyclooxygenase path- 
way of srachidonic acid (10). The mechanisms leading to 
the isolated droo in U-6-Keto-PGF,.. levels in oatients 
from group B cannot be ascertained from data in this 
study. These patients showed basal levels of U-6-K&0- 
PGF,. significantly higher than those in group A. Wlteth- 
er this previous increase in activity of the prostacyclin syn- 
thesizing pathway may predispose it to failure after furo- 
semide administration remains to he investigated. 
@a the other hand, mechanisms unrelated to renal 
prostaglandina might contribute, to some extent. to 
changes in CCrafterfurosemide. This druginhibits the to- 
huloglomerular feedback mechanism which is involved in 
the maintenance of renal perfusion pressure during 
changes in arterial pressure (22). Early and transitory 
changes in arterial pressure have been observed after fu- 
rosemide administration in patients with congestive cardi- 
ac failure (23). Although similar events remain to he veti- 
tied in cirrhotic patients (24), it is possible that variations 
in arterial pressure in the post-furosemide period, might 
induce coupled changes in CCr in the presence of an im- 
paired tubuloglomerular feedback mechanism (22). 
In summary, this study suggests that renal prostacydin 
may play a major role in mediating the glomerular effects 
of fwosemide in cirrhotic phtients with ascites and that a 
drop in its synthesis may contribute to the acute impair- 
ment of renal function occurring in some of these patients 
after furoscmide administration. 
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